|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
Description: Record adverse events, serious adverse events, and deathsMeasure: Adverse events, serious adverse events, and deaths Time: 14 days
Description: Record adverse events, serious adverse events, and deathsMeasure: Adverse events, serious adverse events, and deaths Time: 28 days
Description: Measurement of the area under the curve of anti SARS CoV-2 immunoglobulinMeasure: AUC0-7 of Anti SARS CoV-2 antibodies Time: 7 days
Description: Evaluate virus neutralization activity of patient's plasmaMeasure: Neutralization activity Time: 7 days
Description: Time patient spent in hospitalMeasure: Duration of Hospitalization Time: 84 days
Description: Score on the 6 point ordinate scaleMeasure: Clinical status on the 6 point ordinate scale Time: 84 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports